title: Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.
abstract: Vitamin K antagonists (VKAs) are effective antithrombotic agents and advocated in guidelines for the management of cardiovascular disease. However, in the trials underlying these guidelines, many patients were excluded. We performed a case-control study in 993 patients receiving VKAs, who required hospitalization for bleeding, and contrasted them to 993 matched control patients on VKAs, who were hospitalized for an infection. We analyzed whether patients and controls would have been eligible for the clinical trials on which their indication for anticoagulation was based, and estimated the risk of hemorrhage associated with exclusion criteria as applied in those trials. Approximately one quarter (23% [95% CI: 21%-26%]) of controls had one or more exclusion criteria for the trials, supporting the use of anticoagulation for their condition. Forty percent of patients presenting with bleeding had one or more exclusion criteria (95% CI: 37%-43%). Having one exclusion criterion resulted in a 2.9-fold increased risk of bleeding (95% CI: 2.2-3.9), and this risk increased sharply when more than one exclusion criterion was present. VKAs are often prescribed to patients who would not have qualified for clinical trials, and in these patients a careful consideration should be made regarding the expected efficacy and the risk of bleeding.
authors.affiliation: Department of Internal Medicine/Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl
authors.forename: Marcel
authors.initials: M
authors.lastname: Levi
authors.forename: G Kees
authors.initials: GK
authors.lastname: Hovingh
authors.forename: Suzanne C
authors.initials: SC
authors.lastname: Cannegieter
authors.forename: Marinus
authors.initials: M
authors.lastname: Vermeulen
authors.forename: Harry R
authors.initials: HR
authors.lastname: Büller
authors.forename: Frits R
authors.initials: FR
authors.lastname: Rosendaal
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D006470:Hemorrhage / Q000209:etiology*; D006760:Hospitalization; D006801:Humans; D008297:Male; D018579:Patient Selection; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D014812:Vitamin K